Inhibitor of indoleamine-2,3-dioxygenase (IDO)
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
W is a bond;
Q is a bond;
Y is —N═;
R 1 is —C(═O)OH, —C(═O)OR 10 , or
R 2 and R 3 are each independently hydrogen, halogen, C 1 -C 6 alkyl, or R 2 and R 3 are joined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or tetrahydropyranyl ring, each of which is unsubstituted or substituted with fluorine;
R 4 and R 5 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 5 -C 8 cycloalkenyl, C 2 -C 10 alkynyl, C 3 -C 8 cycloalkyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with a substituent selected from hydroxyl, methyl, CF 3 , cyclopropyl, fluorine, C 1-6 alkoxy substituted phenyl, CF 30 -phenyl, C 1-6 alkoxy, and CF 3 O—; or R 4 and R 5 are joined together with the N they are attached to form one of the following:
R 6 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl; C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 5 -C 8 cycloalkenyl, aryl, 4 to 7-membered monocyclic heterocyclyl, 7 to 10-membered bicyclic heterocyclyl, 5 to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, wherein the alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl is unsubstituted or substituted with a substituent selected from C 1 -C 6 alkyl, halogen, —CN, OH, C 1 -C 6 alkoxy, and CH 3 SO 2 ; and
R 10 is substituted or unsubstituted C 1 -C 6 alkyl, or substituted or unsubstituted C 2 -C 6 alkenyl.
2. The compound of claim 1 , wherein R 1 is: —C(═O)OH or
3. The compound of claim 1 , wherein R 2 and R 3 are joined to form an unsubstituted cyclopropyl, unsubstituted cyclobutyl,
unsubstituted cyclopentyl, or unsubstituted cyclohexyl ring.
4. The compound of claim 1 , wherein R 4 and R 5 are each independently C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with a substituent selected from hydroxyl, methyl, CF 3 , cyclopropyl, fluorine, C 1-6 alkoxy substituted phenyl, CF 3 O-phenyl, C 1-6 alkoxy, and CF 3 O—.
5. The compound of claim 4 , wherein R 4 and R 5 are each independently of the formula:
wherein R is C 1 -C 6 alkyl or CF 3 .
6. The compound of claim 1 , wherein R 6 is of the formula:
wherein R 6A is hydrogen, C 1 -C 6 alkyl, halogen, —CN, OR 6a , or CH 3 SO 2 ;
wherein R 6a is hydrogen, or C 1 -C 6 alkyl; and
k is 0, 1, or 2.
7. The compound of claim 1 , wherein R 6 is of the formula:
8. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
10. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.